These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
95 related items for PubMed ID: 19475539
1. Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response. Bundgaard C, Larsen F, Kreilgaard M, Brennum LT, Olsen CK. Biopharm Drug Dispos; 2009 May; 30(4):209-20. PubMed ID: 19475539 [Abstract] [Full Text] [Related]
2. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. Olsen CK, Brennum LT, Kreilgaard M. Eur J Pharmacol; 2008 Apr 28; 584(2-3):318-27. PubMed ID: 18325493 [Abstract] [Full Text] [Related]
5. In vivo occupation of dopamine D1, D2 and serotonin (5-HT)2A receptors by sertindole in the rat brain. Takahashi Y, Kusumi I, Ishikane T, Matsubara S, Koyama T. J Psychiatry Neurosci; 1998 May 28; 23(3):157-62. PubMed ID: 9595889 [Abstract] [Full Text] [Related]
11. Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. Didriksen M, Kreilgaard M, Arnt J. Eur J Pharmacol; 2006 Aug 07; 542(1-3):108-15. PubMed ID: 16806167 [Abstract] [Full Text] [Related]
12. Predicting the dopamine D2 receptor occupancy of ropinirole in rats using positron emission tomography and pharmacokinetic-pharmacodynamic modeling. Huang C, Wang Z, Liu L, Liu X, Dong J, Xu Q, Zhang B, Miao L. Xenobiotica; 2019 Feb 07; 49(2):143-151. PubMed ID: 29334326 [Abstract] [Full Text] [Related]
14. The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. Natesan S, Svensson KA, Reckless GE, Nobrega JN, Barlow KB, Johansson AM, Kapur S. J Pharmacol Exp Ther; 2006 Aug 07; 318(2):810-8. PubMed ID: 16648369 [Abstract] [Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic modeling of the hydroxy lerisetron metabolite L6-OH in rats: an integrated parent-metabolite model. Ortega F, Quintana A, Suárez E, Lukas JC, Jauregizar N, de la Fuente L, Lucero ML, Gonzalo A, Orjales A, Calvo R. Pharm Res; 2005 Nov 07; 22(11):1769-82. PubMed ID: 16158214 [Abstract] [Full Text] [Related]
19. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S. Neuropsychopharmacology; 2006 Sep 07; 31(9):1854-63. PubMed ID: 16319908 [Abstract] [Full Text] [Related]